AIN
XX Pharma Breakthrough XX

XX Pharma Breakthrough XX

location_on Queensland ,  Australia

Please note:
Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. This platform is targeted solely at investors who are sufficiently sophisticated to understand these risks and make their own investment decisions. Investors are encouraged to review and evaluate the investments and determine at their own discretion, the appropriateness of making the particular investment. The information on this website is provided for informational purposes only, but we cannot guarantee that the information is accurate or complete. We strongly encourage investors to complete their own due diligence with licensed professionals, prior to making any investment and will not offer any legal or tax advice.

Short Summary

Implicit Bioscience is advancing IC14, a first-in-class antibody that switches off uncontrolled inflammation at its source, unlocking new treatments for ALS, acute respiratory distress, heart failure, and other diseases on the auto-immune scale

Highlights

  • First-in-Class global breakthrough in pharmaceticals most challenging space
  • Fully Established clinical safety in 8-year human and animal trial studies
  • World-class advisory panel, board and management team.
  • Substantial interest from 'Big Pharma' with several accessing our Data Room
  • Anticipated vastly shortened runway to commercialisation.

Overview

Target $3,300,000
Minimum $15,000
Investment Raised $2,600,000
Previous Rounds $6,600,000
Stage Pre-Startup/R&D
Investor Role Silent

Ask a question
Got a question about this project?

Similar Projects